March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.
Atopic dermatitis is a type of skin inflammation also known as eczema, which in severe cases causes intense constant itching.
(Reporting By Deena Beasley and Bill Berkrot; Editing by Chizu Nomiyama)
BRIEF-Ironhorse announces Q1 2017 financial and operating results
* Ironhorse announces Q1 2017 financial and operating results